Tumor-specific signaling to p53 is mimicked by Mdm2 inactivation in zebrafish: Insights from mdm2 and mdm4 mutant zebrafish

Oncogene

Volumn 34, Issue 48, 2015, Pages 5933-5941

  Chua, J S ^a   Liew, H P ^a   Guo, L ^b   Lane, D P ^a  

^a Agency for Science   (Singapore)

^b Aegis Biotech   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; UBIQUITIN PROTEIN LIGASE E3; ZINC FINGER NUCLEASE; MDM2 PROTEIN, ZEBRAFISH; MDM4 PROTEIN, ZEBRAFISH; ZEBRAFISH PROTEIN;

ADULTHOOD; ALLELE; ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL STAGE; ENZYME ACTIVITY; ESSENTIAL GENE; GENE MUTATION; GENOTYPE; LETHALITY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ZEBRA FISH; ANIMAL; EMBRYOLOGY; EYE TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; NONMAMMALIAN EMBRYO; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC ANIMAL; WESTERN BLOTTING;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BLOTTING, WESTERN; EMBRYO, NONMAMMALIAN; EYE NEOPLASMS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; MICE; MUTATION; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MDM2; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84948576627     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.57     Document Type: Article

References (42)

1. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
2. MacInnes AW, Amsterdam A, Whittaker CA, Hopkins N, Lees JA. Loss of p53 synthesis in zebrafish tumors with ribosomal protein gene mutations. Proc Natl Acad Sci USA 2008; 105: 10408-10413.
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
4. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
5. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857-860.
6. Yang Y, Li CC, Weissman AM. Regulating the p53 system through ubiquitination. Oncogene 2004; 23: 2096-2106.
7. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000; 275: 8945-8951.
8. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 1996; 15: 5349-5357.
9. Sharp DA, Kratowicz SA, Sank MJ, George DL. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem 1999; 274: 38189-38196.
10. Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci USA 2003; 100: 12009-12014.
11. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006; 13: 927-934.
12. Huang L, Yan Z, Liao X, Li Y, Yang J, Wang ZG et al. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci USA 2011; 108: 12001-12006.
13. Pant V, Xiong S, Iwakuma T, Quintas-Cardama A, Lozano G. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci USA 2011; 108: 11995-12000.
14. Lane DP, Cheok CF, Brown C, Madhumalar A, Ghadessy FJ, Verma C. Mdm2 and p53 are highly conserved from placozoans to man. Cell Cycle 2010; 9: 540-547.
15. Lane DP, Verma C. Mdm2 in evolution. Genes Cancer 2012; 3: 320-324.
16. Lee KC, Goh WL, Xu M, Kua N, Lunny D, Wong JS et al. Detection of the p53 response in zebrafish embryos using new monoclonal antibodies. Oncogene 2008; 27: 629-640.
17. Langheinrich U, Hennen E, Stott G, Vacun G. Zebrafish as a model organism for the identification and characterization of drugs and genes affecting p53 signaling. Curr Biol 2002; 12: 2023-2028.
18. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378: 206-208.
19. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378: 203-206.
20. Guo L, Liew HP, Camus S, Goh AM, Chee LL, Lunny DP et al. Ionizing radiation induces a dramatic persistence of p53 protein accumulation and DNA damage signaling in mutant p53 zebrafish. Oncogene 2013; 32: 4009-4016.
21. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008; 22: 1337-1344.
22. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry-Revisited! J Pathol 1994; 172: 1-4.
23. Robu ME, Larson JD, Nasevicius A, Beiraghi S, Brenner C, Farber SA et al. p53 activation by knockdown technologies. PLoS Genet 2007; 3: e78.
24. Chavez-Reyes A, Parant JM, Amelse LL, de Oca Luna RM, Korsmeyer SJ, Lozano G. Switching mechanisms of cell death in mdm2-and mdm4-null mice by deletion of p53 downstream targets. Cancer Res 2003; 63: 8664-8669.
25. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 2001; 29: 92-95.
26. Geyer RK, Yu ZK, Maki CG. The MDM2 ING-finger domain is required to promote p53 nuclear export. Nat Cell Biol 2000; 2: 569-573.
27. Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindstrom MS et al. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 2007; 12: 355-366.
28. Berghmans S, Murphey RD, Wienholds E, Neuberg D, Kutok JL, Fletcher CD et al. tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci USA 2005; 102: 407-412.
29. Zhang Y, Xiong S, Li Q, Hu S, Tashakori M, Van Pelt C et al. Tissue-specific and agedependent effects of global Mdm2 loss. J Pathol 2014; 233: 380-391.
30. Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G et al. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 2006; 103: 3232-3237.
31. Meng X, Noyes MB, Zhu LJ, Lawson ND, Wolfe SA. Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases. Nat Biotechnol 2008; 26: 695-701.
32. Doyon Y, McCammon JM, Miller JC, Faraji F, Ngo C, Katibah GE et al. Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol 2008; 26: 702-708.
33. Steinman HA, Hoover KM, Keeler ML, Sands AT, Jones SN. Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development. Oncogene 2005; 24: 7935-7940.
34. Finch RA, Donoviel DB, Potter D, Shi M, Fan A, Freed DD et al. mdmx is a negative regulator of p53 activity in vivo. Cancer Res 2002; 62: 3221-3225.
35. Migliorini D, Lazzerini Denchi E, Danovi D, Jochemsen A, Capillo M, Gobbi A et al. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 2002; 22: 5527-5538.
36. Taylor JS, Braasch I, Frickey T, Meyer A, Van de Peer Y. Genome duplication, a trait shared by 22000 species of ray-finned fish. Genome Res 2003; 13: 382-390.
37. Doumont G, Martoriati A, Beekman C, Bogaerts S, Mee PJ, Bureau F et al. G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv. EMBO J 2005; 24: 3093-3103.
38. Pant V, Lozano G. Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev 2014; 28: 1739-1751.
39. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, Perry ME. mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 2003; 23: 462-472.
40. Peller S. Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. Semin Cancer Biol 1998; 8: 379-387.
41. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861-872.
42. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-860.